Mirum Pharmaceuticals, Inc. (MIRM) Q1 FY26 Earnings Call

Raised revenue guidance and upcoming FOP approval create near-term catalysts, but pivotal data and GAAP profitability remain key uncertainties.

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Length39 minutes
EPS$-0.39
EPS consensus$-0.40
Revenue$159.9M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25 · Q2 FY25

All MIRM earnings · Back to MIRM overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.